SCHEMBL20958045

SCHEMBL20958045

CC1(c2cc3cc(N)c(F)cc3n2CC(O)COCc2ccccc2)COC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RGS12 O14924 4/20 0.41
▸ APOBEC3A P31941 3/20 0.41
▸ APOBEC3G Q9HC16 3/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ TP53 P04637 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ CYP2D6 P10635 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ AGER Q15109 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA7 P43166 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CTDSP1 Q9GZU7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20958044 1.00 RGS12 (0.41) RGS12APOBEC3AAPOBEC3GMEN1KMT2A
SCHEMBL28667040 0.89 MEN1 (0.39) RGS12APOBEC3AAPOBEC3GMEN1KMT2A
SCHEMBL28667038 0.89 MEN1 (0.39) RGS12APOBEC3AAPOBEC3GMEN1KMT2A
SCHEMBL28649162 0.84 MEN1 (0.41) RGS12APOBEC3AAPOBEC3GMEN1KMT2A
SCHEMBL28649165 0.84 MEN1 (0.41) RGS12APOBEC3AAPOBEC3GMEN1KMT2A
SCHEMBL28669781 0.83 MEN1 (0.40) RGS12APOBEC3AAPOBEC3GMEN1KMT2A
SCHEMBL28669783 0.83 MEN1 (0.40) RGS12APOBEC3AAPOBEC3GMEN1KMT2A
SCHEMBL28667047 0.80 RGS12 (0.44) RGS12APOBEC3AAPOBEC3GMEN1KMT2A
SCHEMBL28667045 0.80 RGS12 (0.44) RGS12APOBEC3AAPOBEC3GMEN1KMT2A
SCHEMBL349637 0.79 RGS12 (0.42) RGS12APOBEC3AAPOBEC3GMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113912617-A Substituted tricycles and methods of use 艾伯维公司 2022-01-11 — — CN disclosed
CN-108349930-B Substituted tricycles and methods of use 艾伯维公司 2021-10-29 — — CN disclosed
US-20190135827-A1 Substituted Tricyclics and Method of Use ABBVIE SARL (LU) 2019-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135827-A1 Substituted Tricyclics and Method of Use CFTR, F12, CHRM2 RGS12 1066/4885APOBEC3A 4601/4885APOBEC3G 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback